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Dr. Goldstein et al. have published their data on cytosine–
adenine–guanine (CAG) trinucleotide repeats on an androgen
receptor (AR) gene among a select group of vulvodynia cases and
noneffected controls and have argued that their data suggest these
women with vulvodynia who had started combined oral contra-
ceptives (COCs) prior to pain onset, and whose pain resolved after
COCs were discontinued, were more likely than controls to have
a greater number of CAG repeats in the AR gene and were also
likely to have a lower free testosterone level [1]. They suggest this
ﬁnding identiﬁes a subgroup of genetically predisposed women in
whom oral contraceptives are more likely to instigate their vulvar
pain that may be relieved on discontinuation of this medication.
Unfortunately, the study as conducted compared two groups
who differed in a number of ways, making interpretation of the
results problematic. In a case control study, the goal is to have the
groups as similar as possible, with the variable in question (a
genetic difference predisposing to vulvodynia that is instigated by
COCs and resolving when COCs are discontinued) being the
main difference between the two groups, thereby allowing one to
conclude that a difference noted may be associated with that vari-
able. The authors proposed to demonstrate a gene–environment
interaction but have looked at only one part of such a model. In
the reported study, all women were taking COCs, but one group
had developed vulvodynia and the other had not; hence, the dif-
ferences noted in CAG repeats on the AR gene might be related
to the susceptibility to vulvodynia in general, rather than to the
use of COCs. In addition, remission in vulvodynia is increasingly
understood to occur [2,3], and hence the genetic proﬁle of those
with remission after COCs were discontinued needs to be com-
pared with that of those whose vulvar pain did not remit when
COCs are removed. A number of other interpretations of the
data would be consistent with the ﬁndings. The genetic differ-
ence noted could have also been related to differences previously
reported among those with and without vulvodynia, such as
having comorbid pain conditions (ﬁbromyalgia, interstitial cysti-
tis, irritable bowel disorder, temporomandibular dysfunction,
etc.) [4], depression, or having increased sensitivity itself [5]. All
of these are possible interpretations of the data presented, but
they, like the interpretation proposed in the article, are not prov-
able with the data provided.
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Dear Editor,
We are pleased to have this opportunity to further discuss our
study and agree that there are important caveats and limitations to
our ﬁndings, as we have already delineated in our publication.
While there may be alternative interpretations to the data, we
believe that our conclusions are the most biologically plausible and
consistent with the data. In our study, the cases were women who
developed vestibulodynia after starting combined hormonal con-
traceptives (CHCs). The vestibulodynia resolved after cessation of
CHCs and treatment with topical estradiol and testosterone. By
their mechanisms of action, CHCs cause an endocrinopathy due to
a decrease in serum-free testosterone. We postulate that it is the
combination of low free testosterone and the longer CAG repeat
polymorphism in the androgen receptor gene that increases the
risk of vestibulodynia.
This perspective was further supported by the fact that the
control group had a lower free testosterone than the subject group
but had longer CAG repeat lengths overall and did not develop
vestibulodynia. Further, the members of the control group were
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